Eads & Heald Wealth Management Sells 1,102 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Eads & Heald Wealth Management lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 34.7% during the fourth quarter, Holdings Channel reports. The firm owned 2,073 shares of the medical research company’s stock after selling 1,102 shares during the period. Eads & Heald Wealth Management’s holdings in Charles River Laboratories International were worth $490,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Regency Capital Management Inc. DE bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at $3,703,000. DekaBank Deutsche Girozentrale raised its holdings in Charles River Laboratories International by 98.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after acquiring an additional 6,997 shares during the period. AMG National Trust Bank bought a new position in Charles River Laboratories International in the 3rd quarter worth $1,119,000. DAVENPORT & Co LLC bought a new position in Charles River Laboratories International in the 4th quarter worth $1,904,000. Finally, CGN Advisors LLC bought a new position in Charles River Laboratories International in the 4th quarter worth $1,663,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded down $3.54 during trading hours on Tuesday, reaching $232.39. 26,877 shares of the stock were exchanged, compared to its average volume of 544,664. The company has a market cap of $11.97 billion, a P/E ratio of 25.62, a price-to-earnings-growth ratio of 1.89 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock has a 50 day moving average of $253.00 and a two-hundred day moving average of $220.60.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. During the same period last year, the company posted $2.98 EPS. The firm’s quarterly revenue was down 7.9% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CRL shares. Argus lifted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Citigroup boosted their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. UBS Group upped their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).